Intraperitoneal gene therapy [0.03%]
腹腔内基因治疗
S Madhusudan,T S Ganesan
S Madhusudan
K A Cengel,E Glatstein,S M Hahn
K A Cengel
Peritoneal carcinomatosis and sarcomatosis are generally incurable problems for which there are few good treatment options. Intraperitoneal PDT is potentially an ideal therapy for peritoneal carcinomatosis because of its relatively superfic...
M A Ströhlein,M M Heiss
M A Ströhlein
Intraperitoneal immunotherapy actually is a promising concept for treatment of peritoneal carcinomatosis for several reasons: The use of specifically engineered therapy in terms of antibodies or stimulated T lymphocytes against epithelial t...
S Samel,M Löhr
S Samel
The prognosis of peritoneal spread from gastrointestinal cancer and subsequent malignant ascites is poor, and current medical treatments available are mostly ineffective. Targeted chemotherapy with intraperitoneal prodrug activation may be ...
Gerhild Becker
Gerhild Becker
T Boterberg,W Duthoy,W De Neve
T Boterberg
Systemic chemotherapy in patients with peritoneal carcinomatosis from non colorectal origin [0.03%]
非结直肠来源腹膜癌转移患者的系统化疗
S Van Lierde,H Denys,M Peeters
S Van Lierde
Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer [0.03%]
结直肠癌腹膜转移的系统化疗
G Folprecht,C H Köhne,M P Lutz
G Folprecht
Detection and treatment of recurrent disease after cytoreduction and HIPEC [0.03%]
减瘤术和HIPEC后的复发性疾病的诊断与治疗
V J Verwaal
V J Verwaal
M Deraco,D Baratti,S Kusamura
M Deraco